Redefining HER2-ultralow Detection: Mindpeak & AstraZeneca at ASCO 2025

June 18, 2025

Mindpeak GmbH is looking back at an unforgettable experience at this year’s ASCO2025!

Seeing our work presented in front of 2,000+ experts on the world’s leading oncology stage was more than an honor - it was a defining moment in Mindpeak’s mission to transform cancer diagnostics with AI.

This year stood out as we reached key milestones - most notably, unveiling the transformative results of our collaboration with AstraZeneca, driving the evolution of breast cancer therapies.

Key Highlights:

AI-powered HER2-ultralow detection: Our technology, deployed in one of the world’s largest clinical studies, enabled HER2-ultralow detection at scale - supporting AstraZeneca's Enhertu clinical program.

Clinical Impact: As seen in our session, our AI was instrumental in generating reproducible, high-quality data that contributes to more personalized treatment strategies for breast cancer patients.

Digital pathology at center stage: With our tech featured across multiple sessions and posters, Mindpeak's vision of accessible, automated cancer diagnostics is becoming a reality.

#ASCO2025 wasn't just about showcasing innovation - it was about proving real-world impact.

We’re building AI that scales, adapts, and empowers clinicians worldwide. The response we received confirmed: we’re solving the right problems, in the right way.

A heartfelt thank you to our partners at AstraZeneca, to the many labs and clinicians who made this possible, and to the incredible team at Mindpeak. Your dedication and ambition are the heartbeat of this movement.

Let’s keep pushing forward - the future of AI-driven cancer care is happening now.

In the News

Related reading

We’re proud to see our VP Precision Medicine, Patrick Frey, featured in Oncology Times sharing his perspective on one of oncology’s most urgent challenges – achieving true equity in biomarker testing.
In the News
8 min read

Mindpeak in Oncology Times

We’re proud to see our VP Precision Medicine, Patrick Frey, featured in Oncology Times sharing his perspective on one of oncology’s most urgent challenges – achieving true equity in biomarker testing.

We’re proud to see our VP Precision Medicine, Patrick Frey, featured in Oncology Times sharing his perspective on one of oncology’s most urgent challenges – achieving true equity in biomarker testing.

As Patrick notes, the conversation must move from if to how. The science and technology already exist; now it’s about ensuring every patient, everywhere, can access and benefit from them.

At Mindpeak, we believe AI-powered pathology can help close that gap – supporting faster, more consistent insights that make precision medicine truly accessible.

In the News
8 min read

AI-Enabled Pathology: De-risking Oncology Drug Development

We are delighted to share that Aurélie Fugon, VP Predictive AI Solutions at Mindpeak, is featured in Life Science Daily News.

In her article, Aurélie outlines how AI-supported biomarker-driven strategies can reduce variability in pathology, improve the consistency of patient selection and help de-risk late-stage trials.

All key enablers of more reliable, data-rich clinical decision-making. With Aurélie’s leadership, we’re strengthening collaborations with pharma, biotech and clinical partners to help bring reproducible, scalable biomarker assessment into real-world research settings, shaping the future of predictive AI in precision oncology.

Read the full article here: https://lifesciencedaily.news/ai-enabled-pathology-de-risking-oncology-drug-development/

In the News
8 min read

United by Unique: Advancing Personalised Cancer Care on World Cancer Day

Every person with cancer is unique. So is every diagnosis - and every pathology sample that informs it.

This year’s World Cancer Day theme continues the focus on United by Unique, highlighting the importance of early detection, equitable access, and truly personalised care. It is a powerful reminder that behind every case is an individual with distinct biology, circumstances, and needs.

At Mindpeak, we believe precision medicine should be a right, not a privilege. Scientific and technological advances have transformed what is possible in cancer diagnostics. The challenge now is ensuring these innovations reach patients in ways that reflect their individuality.

Advanced AI models in digital pathology can help bridge this gap. By accelerating insights from complex tissue data and supporting clinicians with consistent, high-quality analysis, AI contributes to faster, more precise and more personalised decision-making.

On World Cancer Day, we stand with the global community in raising awareness and championing approaches that put people first. When we see the person before the disease, we move closer to a future where every individual’s uniqueness is recognized - and reflected - in their care.

Ready to advance your diagnostics

Connect with our team to explore how precision pathology works in your setting